UBS upgraded UnitedHealth (UNH) to buy from neutral. The analyst notes that UNH’s “strong” 3Q is a “clearing event that should pave the way for improved valuation.” UBS raised UNH’s price target to $640 from $520. Jenny Horne discusses this along with Pfizer (PFE) which cut its full-year guidance as demand for Covid-19 vaccines fall. PFE’s shares are near a 52-week low. Tune in to find out more about the stock market today.